Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Debt (2020 - 2023)

Historic Total Debt for C4 Therapeutics (CCCC) over the last 4 years, with Q2 2023 value amounting to $10.3 million.

  • C4 Therapeutics' Total Debt fell 707.61% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year decrease of 707.61%. This contributed to the annual value of $11.5 million for FY2022, which is 663.08% up from last year.
  • C4 Therapeutics' Total Debt amounted to $10.3 million in Q2 2023, which was down 707.61% from $10.9 million recorded in Q1 2023.
  • In the past 5 years, C4 Therapeutics' Total Debt registered a high of $11.5 million during Q4 2022, and its lowest value of $9.9 million during Q3 2020.
  • For the 4-year period, C4 Therapeutics' Total Debt averaged around $10.7 million, with its median value being $10.7 million (2021).
  • Its Total Debt has fluctuated over the past 5 years, first surged by 719.85% in 2021, then plummeted by 707.61% in 2023.
  • C4 Therapeutics' Total Debt (Quarter) stood at $10.1 million in 2020, then grew by 7.12% to $10.8 million in 2021, then grew by 6.63% to $11.5 million in 2022, then fell by 9.99% to $10.3 million in 2023.
  • Its Total Debt stands at $10.3 million for Q2 2023, versus $10.9 million for Q1 2023 and $11.5 million for Q4 2022.